Glycopyrronium bromide is a medication of the muscarinic anticholinergic group; it blocks muscarinic receptors, thus inhibiting cholinergic transmission.
It does not cross the blood–brain barrier and consequently has no to few central effects. A synthetic quaternary amine, it is available in oral and intravenous (i.v.) forms. The cation, which is the active moiety, is also known as glycopyrrolate.
Reversal of neuromuscular blockade: 200 mcg for each 1 mg of neostigmine or 5 mg of pyridostigmine.
Reduction of secretions. Pre-op: 4 mcg/kg via IM administration 30-60 mins before procedure. Intraoperative: 0.1 mg via IV administration, repeat at 2-3 min intervals when needed. Max: 400 mcg/dose.
Peptic ulcer: 0.1-0.2 mg 3-4 times/day.
Adverse drug reactions: xerostomia; loss of taste, nausea, vomiting, constipation, reduced sweating; urinary hesitancy and retention; blurred vision; cycloplegia; increased ocular tension; tachycardia; palpitation; headache, anxiety, bloated feeling, impotence, skin reactions.